CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ÀüÈ«Àç
  • ¾Ï¼¾ÅÍÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£¾Ï/Ãé´ãµµ¾Ï
  • Á÷ À§: ºÎ±³¼ö(¾Ï¼¾ÅÍÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
183 (±¹¿Ü)SCIE Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites
182 (±¹¿Ü)SCI A multicenter phase II study of sorafenib in combination with erlotinibin patients with advanced non-small cell lung cancer (KCSG-0806)
181 (±¹¿Ü)SCI Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabineresistant pancreatic cancer cells
180 (±¹¿Ü)±âŸ Targeting the indoleamine 2,3-dioxygenase pathway in cancer
179 (±¹¿Ü)SCI Methylation-dependent regulation of HIF-1a stability restricts retinal and tumour angiogenesis
178 (±¹¿Ü)SCI A randomized phase II trial of ERCC1 and RRM1 mRNA expression?based chemotherapy versus docetaxel/carboplatin in advanced non?small cell lung cancer
177 (±¹³»)KCI A case of atypical hemolytic uremic syndrome associated with the c.1273C£¾T mutation in the complement C3 gene
176 (±¹¿Ü)SCIE Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
175 (±¹¿Ü)SCI Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non?Small-Cell Lung Cancer: KCSG-LU05-04
174 (±¹¿Ü)SCI Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 18 19 20 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729